Tonix Pharmaceuticals Holding Corp.

As of November 9, 2023, Tonix Pharmaceuticals is considered risky and overvalued due to high financial ratios and negative returns, underperforming the S&P 500 significantly.

As of November 9, 2023, Tonix Pharmaceuticals is considered risky and overvalued, with concerning financial metrics and a one-year stock performance of -74.78%, significantly underperforming the S&P 500's 10.26% return.

As of June 3, 2025, the trend has shifted to bullish with moderate strength, supported by a bullish daily moving average, monthly RSI, and weekly KST, though caution is advised due to bearish monthly Bollinger Bands.

As of March 2022, the management team of Tonix Pharmaceuticals includes Dr. Seth Lederman as Chairman, President, and CEO, with Mr. James Treco as Lead Independent Director, and Independent Directors Mr. Richard Bagger, Ms. Margaret Bell, Dr. Daniel Goodman, and Brig. Gen. (Retd.) David Grange.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders. As of March 2025, it reported net sales of $2 million and a net loss of $17 million, with a market cap of $256.91 million.

As of Jun 18, Tonix Pharmaceuticals Holding Corp. has a market capitalization of 256.91 million, with net sales of 10.04 million and a net profit of -131.93 million over the latest four quarters. As of Dec 24, shareholder's funds are 139.56 million, and total assets are 162.89 million.